Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, T2N 4N1, Canada.
Br J Pharmacol. 2019 Apr;176(8):1000-1008. doi: 10.1111/bph.14178. Epub 2018 Apr 16.
Eicosanoids play important roles in modulating inflammation throughout the body. The gastrointestinal (GI) tract, in part because of its intimate relationship with the gut microbiota, is in a constant state of low-grade inflammation. Eicosanoids like PGs, lipoxins and leukotrienes play essential roles in maintenance of mucosal integrity. On the other hand, in some circumstances, these mediators can become major drivers of inflammatory processes when the lining of the GI tract is breached. Drugs such as nonsteroidal anti-inflammatories, by altering the production of various eicosanoids, can dramatically impact the ability of the GI tract to respond appropriately to injury. Disorders such as inflammatory bowel disease appear to be driven in part by altered production of eicosanoids. Several classes of drugs have been developed that target eicosanoids. LINKED ARTICLES: This article is part of a themed section on Eicosanoids 35 years from the 1982 Nobel: where are we now? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.8/issuetoc.
类二十烷酸在调节全身炎症中发挥着重要作用。胃肠道（GI）在一定程度上由于与肠道微生物群的密切关系，处于慢性低度炎症状态。类二十烷酸如 PGs、脂氧素和白三烯在维持粘膜完整性方面发挥着重要作用。另一方面，在某些情况下，当胃肠道内层被破坏时，这些介质可能成为炎症过程的主要驱动因素。非甾体类抗炎药等药物通过改变各种类二十烷酸的产生，会显著影响胃肠道对损伤做出适当反应的能力。炎症性肠病等疾病似乎部分是由类二十烷酸的产生改变驱动的。已经开发出几类靶向类二十烷酸的药物。
本文是关于类二十烷酸的主题部分，距 1982 年诺贝尔奖 35 年：我们现在在哪里？要查看该部分中的其他文章，请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.8/issuetoc/。
